(Q34421664)

2 August 2017

1 reference

title

The mechanisms of thrombotic risk induced by hormone replacement therapy (English)

1 reference

2 August 2017

A Cano

1

1 reference

2 August 2017

W M Van Baal

series ordinal

2

1 reference

2 August 2017

publication date

1 October 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

40

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

17-38

1 reference

Are we mortgaging the medical profession?

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Hormone replacement therapy and hemostasis: principles of a complex interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Venous thrombosis: a multicausal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Plasminogen-activator inhibitor type 1 and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

P-selectin induces the expression of tissue factor on monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Natural history of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The endothelium--the body's largest endocrine gland?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Endothelial function in health and disease: new insights into the genesis of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The protective effects of estrogen on the cardiovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The differential effects of oestrogens and progestins on vascular tone

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Anticoagulantly active heparin-like molecules from vascular tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The emerging concept of vascular remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Intravascular hemodynamic factors responsible for progression of coronary atherosclerosis and development of vulnerable plaque

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Thrombosis and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Risk of venous thromboembolism in users of hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Prospective study of exogenous hormones and risk of pulmonary embolism in women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Hormone replacement therapy and risk of venous thromboembolism: population based case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effects of progestins on cardiovascular diseases: the haemostatic system

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The 'pill scare II' two years later

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: A review

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Recurrent use of newer oral contraceptives and the risk of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The recent saga of cardiovascular disease and safety of oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Oral contraceptives and the risk of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Lung cancer and indoor air pollution arising from Chinese-style cooking among nonsmoking women living in Shanghai, China

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The effects of transdermal oestradiol and oral progestogens on haemostasis variables

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Coagulation activation following estrogen administration to postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Natural anticoagulants, aging, and thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Hemostatic factors according to menopausal status and use of hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Antithrombin III and procoagulant activity: sex differences and effects of the menopause

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in posimenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effects of hormone replacement on hemostasis in spontaneous menopause

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Deficiency of protein C in congenital thrombotic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Mutation in blood coagulation factor V associated with resistance to activated protein C.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Venous thromboembolic disease and ABO blood type. A cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Fibrinogen as a risk factor for stroke and myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Increased mean platelet volume after oestrogen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Estrogen replacement therapy decreases platelet-activating factor-acetylhydrolase activity in post-menopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood--a beneficial effect on atherogenesis and thrombus formation?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effect of 17beta-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Menopausal status and haemostatic variables

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effects of hormone replacement therapy on hemostatic cardiovascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Epidemiology of fibrinogen

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Fibrinogen and plasminogen modifications during oral estradiol replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Plasminogen activator inhibitor in the blood of patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Reduced fibrinolytic activity in coronary heart disease in basal conditions and after exercise

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Fibrinolytic Variables and Cardiovascular Prognosisin Patients With Stable Angina Pectoris Treated With Verapamil or Metoprolol

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Fibrinolytic parameters in women undergoing ovulation induction

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The 20210 G-->A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Prevalence of the prothrombin gene variant 20210 G --> A among patients with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Coagulation factors II, V, VII, and X, prothrombin gene 20210G-->A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Cholesterol reduction yields clinical benefit: impact of statin trials

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Estradiol accelerates functional endothelial recovery after arterial injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

17 beta-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The acute effects of sublingual 17beta-estradiol on the cardiovascular system.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Menopause is associated with endothelial dysfunction in women.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Acute vascular effects of estrogen in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Estrogen acutely increases peripheral blood flow in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Experimental atherosclerosis: effects of oestrogen and atherosclerosis on thromboxane and prostacyclin formation

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Influence of sex hormones on plasma endothelin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

10 Effects of oestrogens and progestogens on coronary atherosclerosis and osteoporosis of monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimal hyperplasia or arterial remodeling induced by balloon catheter injury in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Association of hormone replacement therapy and carotid wall thickness in women with and without diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Effect of oral postmenopausal hormone replacement on progression of atherosclerosis : a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: The Northern California Kaiser Permanente Diabetes Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2801%2900270-5

7 January 2021

10.1016/S0378-5122(01)00270-5

Identifiers

DOI

1 reference

2 August 2017

1 reference